Thimansson, Erik http://orcid.org/0000-0003-4663-8520
Bengtsson, J.
Baubeta, E.
Engman, J.
Flondell-Sité, D.
Bjartell, A.
Zackrisson, S.
Funding for this research was provided by:
Medicinska Fakulteten, Lunds Universitet
Region Skåne
Article History
Received: 12 April 2022
Revised: 26 September 2022
Accepted: 13 October 2022
First Online: 12 November 2022
Change Date: 6 December 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00330-022-09308-y
Declarations
:
: The scientific guarantor of this publication is Professor Sophia Zackrisson.
: The authors of this manuscript declare relationships with the following companies:Sophia Zackrisson has received speaker fees from Siemens Healthcare AB and Pfizer AB. Anders Bjartell has received grants/research supports from Ferring, Bayer and Merck. AB has received honoraria or consultation fees from Astellas, AstraZeneca, Bayer, Janssen, Merck, Recordati and Sandoz. AB has participated in company sponsored speaker´s bureau by Astellas, Bayer, IPSEN, Janssen, Recordati and Sandoz. AB is stock shareholder in LIDDS Pharma, Glactone Pharma and WntResearch.All other authors declare no conflicts of interest.
: Andrea Dahl Sturedahl kindly provided statistical advice for this manuscript.No complex statistical methods were necessary for this paper.
: Written informed consent was waived by the Institutional Review Board.
: Institutional Review Board approval was obtained.
: • retrospective• diagnostic or prognostic study• multicenter study